EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Update

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was the recipient of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 10,340,000 shares, a growth of 9.9% from the December 31st total of 9,410,000 shares. Based on an average trading volume of 956,300 shares, the short-interest ratio is currently 10.8 days.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its position in shares of EyePoint Pharmaceuticals by 112.5% in the 2nd quarter. Renaissance Technologies LLC now owns 152,800 shares of the company’s stock worth $1,329,000 after buying an additional 80,900 shares during the last quarter. Essex Investment Management Co. LLC lifted its holdings in EyePoint Pharmaceuticals by 234.2% in the third quarter. Essex Investment Management Co. LLC now owns 142,144 shares of the company’s stock worth $1,136,000 after acquiring an additional 99,606 shares during the last quarter. Woodstock Corp boosted its stake in EyePoint Pharmaceuticals by 29.1% in the third quarter. Woodstock Corp now owns 71,480 shares of the company’s stock valued at $571,000 after acquiring an additional 16,093 shares during the period. Cyndeo Wealth Partners LLC bought a new position in shares of EyePoint Pharmaceuticals during the third quarter valued at approximately $100,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of EyePoint Pharmaceuticals by 68.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock worth $82,000 after purchasing an additional 4,172 shares during the period. 99.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on EYPT. Scotiabank assumed coverage on EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 target price on the stock. Citigroup assumed coverage on EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective on the stock. Chardan Capital boosted their target price on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Robert W. Baird cut their price target on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, November 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

EyePoint Pharmaceuticals Stock Performance

Shares of NASDAQ:EYPT traded down $0.48 during trading on Monday, hitting $7.17. The company’s stock had a trading volume of 910,150 shares, compared to its average volume of 721,688. The company has a market capitalization of $489.35 million, a PE ratio of -3.59 and a beta of 1.51. EyePoint Pharmaceuticals has a fifty-two week low of $6.90 and a fifty-two week high of $30.99. The stock’s 50-day moving average price is $8.06 and its two-hundred day moving average price is $8.86.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.06). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The business had revenue of $10.52 million during the quarter, compared to analyst estimates of $12.35 million. On average, equities analysts predict that EyePoint Pharmaceuticals will post -2.13 earnings per share for the current fiscal year.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.